Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 50

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 50
---
 against directors and officers, even though an action,
if successful, might benefit us and our shareholders. A shareholder’s investment may be harmed to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions.

We maintain a general liability insurance policy
that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their
capacities as directors or officers.

In any placement agent agreement we enter into
in connection with the sale of Common Shares being registered hereby, the placement agent will agree to indemnify, under certain conditions,
us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities.

Item 7. Recent Sales of Unregistered Securities.

Set forth below are the
sales of all unregistered securities of ours sold by us within the past three years (i.e., since November 25, 2022, up to the date of
this registration statement) which were not registered under the Securities Act. We believe that each of such issuances was exempt from
registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation S under the Securities
Act.

<div align='center'>II-1</div>

On January 11, 2024, we consummated a registered
direct offering of 1,468,000 common shares and 32,000 pre-funded warrants at a price of $1.60 per common share and $1.5999 per pre-funded
warrant share and a simultaneous private placement of unregistered common warrants to purchase an aggregate of up to 1,500,000 common
shares. The unregistered common warrants have an exercise price of $1.60 per share, are immediately exercisable and have a 5-year term
from the issuance date.

On September 17, 2025,
we entered into securities purchase agreements with investors, pursuant to which we shall issue and sell, from time to time, convertible
promissory notes in the aggregate principal amount of up to $10,000,000. We had issued Promissory Notes in the aggregate principal amount of $2.5 million. As of the date hereof, all the outstanding amounts due
under the Promissory Notes were converted into 5,171,460 Common Shares.

The privately placed securities
above were offered and sold pursuant to an exemption from the registration requirements